Vimseltinib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vimseltinib
- DrugBank Accession Number
- DB17520
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 431.5
Monoisotopic: 431.206973073 - Chemical Formula
- C23H25N7O2
- Synonyms
- 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one
- 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone
- 4(3h)-pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
- External IDs
- DCC-3014
- DP-6865
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PX9FTM69BF
- CAS number
- 1628606-05-2
- InChI Key
- TVGAHWWPABTBCX-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
- IUPAC Name
- 3-methyl-5-(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)-2-[(propan-2-yl)amino]-3,4-dihydropyrimidin-4-one
- SMILES
- CC(C)NC1=NC=C(C(=O)N1C)C1=CC=C(OC2=CC=NC(=C2)C2=CN(C)N=C2)C(C)=N1
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Giant Cell Tumor of Tendon Sheath / Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumor / Tenosynovial Giant Cell Tumor, Diffuse / Tenosynovial Giant Cell Tumor, Localized 1 1 Active Not Recruiting Treatment Advanced Sarcoma / Dedifferentiated Liposarcoma / High Grade Sarcoma / Leiomyosarcoma (LMS) / Myxofibrosarcoma / Sarcomas / Undifferentiated Pleomorphic Sarcoma 1 1, 2 Active Not Recruiting Treatment Advanced Malignant Neoplasm / Giant Cell Tumor of Tendon Sheath / Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumor / Tenosynovial Giant Cell Tumor, Diffuse 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0684 mg/mL ALOGPS logP 3.02 ALOGPS logP 2.2 Chemaxon logS -3.8 ALOGPS pKa (Strongest Basic) 4.55 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 97.53 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 131.25 m3·mol-1 Chemaxon Polarizability 46.86 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at February 14, 2023 18:23 / Updated at February 16, 2023 16:08